Biovica corrects patent details in rights issue memorandum

what happened

MFN by Modular Finance reports that Biovica International AB has updated the memorandum for its ongoing rights issue to clarify the company’s patent position. The earlier document said that a PCR-based patent family expiring in 2031 was linked to the technology platform of the current commercial product.

Biovica said DiviTum® TKa is based on an ELISA platform, while the PCR-based patents concern a separate technology acquired by the company in 2017. The patent family covering the ELISA-based assay expired during 2026. The revised memorandum is available on Biovica’s website, with changes made to the sections on market position and intellectual-property risks.

The company said its competitive position is primarily supported by know-how, FDA 510(k) clearance, its US reimbursement position and an extensive clinical evidence base, alongside patents and patent applications covering the use of TKa in immuno-oncology. On 9 September 2026, the board proposed an issue of no more than 97,303,733 B-shares worth approximately SEK 29.2 million before rights issue costs. The extraordinary general meeting approved the resolution on 30 September 2026, and the subscription period runs from 7 October to 21 October 2026.

why it matters

The correction changes how the product’s patent coverage is presented in the offering materials and is therefore relevant to investors assessing intellectual-property risks. The rights issue is ongoing, making the revised memorandum important for participants in the subscription.

instruments